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Non-myeloablative allogenic peripheral blood stem cel transplantation (mini-transplant) is 
becoming a preferred treatment for those recipients in whom the potential toxicity risk of standard 
ablative allogeneic therapy may be acceptable. Graft-versus-tumor effect may be generated against 
epithelial malignancies that are similar to the graft-versus-leukemia activity documented in human 
hematological malignancies. Renal cell carcinoma has been shown to be responsive to immuno-
therapy with recombinant human cytokines and may be an ideal model for exploring this novel therapy. 
Clinical investigations have demonstrated regression of advanced renal cell carcinoma occurs in some 
patients following non-myeloablative allogenic peripheral blood stem cell transplantation. However， 
graft-versus host disease remains a significant toxicity ofnonablative transplantation， and directions for 
further study include the identification of the definitive tumor antigens involved in the graft-versus-
tumor effect and means of selecting those patients who will benefit the most from this prom1Slng 
approach with due regard to improve its safety. 
(Hinyokika Kiyo 51 : 503-507， 2005) 
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Site of metastasis Lung， bone， pleu-ra 
Liver， adrenal， 
pleura， nodes 
Bone， lung， ad- Lung， bone， ad- Lung， bone， Skin， maxillaris， 
kidney， adrenal renal， nodes renaI， brain nodes， vein 
PS 
Fever up No 
Anemia No 
CRP Negative 
Age/sex of donor 69/M 
Source PBSC 
No. of CD34 posi-
tive cels trans- 5.6E+06 
fused/kg 























































Acute GVHD No Grade 111 Grade I No Grade 1 Grade 1 
Chronic GVHD 
Extensive， chron-
ic skin， oral， sal- Skin， liver， G 1 
lvary 
Skin， GI， lung 
extensive chron- No 
ic skin， salivary 
Skin， GI Skin， GI 
Best Response PR PD PR SD SD PR 
Outcome 
SD: 型~~_ of PD: died of carト SD: di~d of PD: died of c廿 SD: di~d of PD: aliv 
15!日;nlaEonmonday6813鳴 maeonmonday26233官;maEon day257 
Abbreviations) M; male， F; female， PS; performance status， IFNa; interferon alpha， IL-2; interleukin-2， PBSC; periphral blood 
stem cel， UCB; umbilical cord blood， GVHD; gra氏ーversus-hostdisease， Flu; t1udarabine， CY ; cyclophosphamide， Bu; busulfan， 
ATG; antithymocyte globulin， TBI; total body irradiation， Mel; melphalan， CyA; cyclosporin A， MMF; mycophenolate mofetil， 
DLI; donor Iymphocyte infusion， GI; gastrointestional， PR; partial response， SD; stable disease， PD; progressive disease， NE; not 
evaluable. 


























l.適応症例の選択， 2.治療プロトコールの確立， 3. 
GVHDの少ない GVT効果の誘導， 4. ドナーの確
保，などが挙げられる.
506 泌尿紀要 51巻 8号 2005年
まず， l.に関しては，腎細胞癌の予後不良に強く
関連する因子として， 1)術後転移が l年以内に出現，











































































1) Motzer RJ， Bander NH and Nanus DM: Renal-cell 
carcinoma. N Engl J Med 335: 865-875， 1996 
2) Horowitz MM， Gale RP， Sondel PM， etal. : Graft-
versus-leukemia reactions after bone marrow 
transplantation. Blood 75: 555-562， 1990 
3) Teshima T， Ordemann R， Reddy P， etal. : Acute 
graft-versus-host disease does not require alloan-
tigen expression on host epithelium. Nat Med 8: 
575-581，2002 
4) Childs RW， Clave E， Tisdale J， etal.: Successful 
treatment of metastatic renal cel carcinoma with a 
nonmyeloablative allogeneic peripheral-blood pro-
genitor-cell transplant: evidence for a graft珊versus-
tumor effect. J Clin Oncol 17: 2044ー2049，1999 
5) Childs RW: Nonmyeloablative allogeneic periph-
eral blood stem-cell transplantation as immuno-
therapy for malignant diseases. Cancer J 6: 179-
187，2000 
6) Rini BI， Zimmerman T， Stadler WM， et al.: 
Allogeneic stem-cell transplantation of renal cel 
cancer after nonmyeloablative chemotherapy : feasi岨
bility， engraftment， and clinical results. J Clin 
Oncol 20: 2017-2024， 2002 
小中.ほか:腎細胞癌 ミニ移植 507 
7) Bregni M， Dodero A， Peccatori j， et al.: 
Nonmyeloablative conditioning followed by 
hematopoietic cel allografting and donor Iympho-
cyte infusions for patients with metastatic renal and 
breast cancer. Blood 99 : 4234-4236， 2002 
8) Pedrazzoli P， Da Prada GA， Giorgiani G， etal. : 
Allogeneic blood stem cel transplantation after a 
reduced-intensity， preparative regimen: a pilot 
study in patients with refractory malignancies. 
Cancer 94: 2409-2415， 2002 
9) Takami A， Asakura H， Koshida K， etal. : Reduced・
intensity allogeneic stem cel transplantation for 
renal cel carcinoma: in vivo evidence of a graft-
versus-tumor effect. Haematologica 89: 375-376， 
2004 
10) Negrier S， Escudier B， Gomez F， etal. : Prognostic 
factors of survival and rapid progression in 782 
patients with metastatic renal carcinomas treated 
by cytokines: a report from the Groupe Francais 
d'Immunotherapie. Ann Oncol 13: 1460-1468， 
2002 
11) Mannering SI， McKenzie jL， Fearnley DB， etal. : 
HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ 
T Iymphocytes respond to dendritic cels pulsed 
with b3a2 peptide and antigen-presenting cells 
exposed to b3a2 containing celllysates. Blood 90・
290-297， 1997 
12) Arai j， Yasukawa M， Ohminami H， et al.: 
Identification of human telomerase reverse trans-
criptase-derived peptides that induce HLA-A24-
restricted antileukemia cytotoxic T Iymphocytes. 
Blood 97: 2903-2907， 2001 
13) Schmidt SM， Schag K， Muller MR， etal.: Survivin 
is a shared tumor-associated antigen expressed in a 
broad variety of malignancies and recognized by 
specific cytotoxic T cels. Blood 102: 571-576， 
2003 
14) Benito AI， Diaz MA， Gonzalez-Vicent M， etal. : 
Hematopoietic stem cel transplantation using 
umbilical cord blood progenitors : review of current 
clinical results. Bone Marrow Transpl 33: 675-
690， 2004 
15) Moscardo F， Sanz GF and Sanz MA: Unrelated-
donor cord blood transplantation for adult hemato幡
logical malignancies. Leukemia Lymphoma 45: 
11-18， 2004 
( Rb恥いecei伐悶叩白吋l仙 n Ma町Y1日3，羽
Accept臼edon May 26， 2005 
